<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E84079FA-C58D-4F3B-8B5C-E13A603D870A"><gtr:id>E84079FA-C58D-4F3B-8B5C-E13A603D870A</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Hay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117512708"><gtr:id>C560187F-6FA7-4DDA-A19B-206C2189490A</gtr:id><gtr:title>Influenza virus replication and the mechanism of action of specific inhibitors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117512708</gtr:grantReference><gtr:abstractText>Two classes for anti-influenza drugs are effective in prophylaxis and treatment of influenza.||Amantadine and rimantadine prevent infection of cells by blocking the M2 ion channel in the virus particle which is essential for entry into cells and subsequent replication of the virus. Our investigations have explained the basis of the selective antiviral activity of the drugs and further elucidated key stages in virus infection. Our current studies of the activities of the NB and CM2 ion channels of influenza B and C viruses, respectively, which differ from that of the M2 channel of influenza A and are not blocked by the two anti-influenza A drugs, will increase our fundamental understanding of their functional roles in virus replication and may provide the basis for developing other, broader spectrum, channel-blocking drugs which are more effective against influenza A, B and C viruses.||Oseltamivir and zanamivir inhibit the neuraminidase (NA), which is involved in the release of virus from infected cells and in the spread within and between individuals. X-ray crystallography of different NA subtypes has identified an additional cavity within the active site of the enzyme which provides an additional target for development of other drugs. These structural studies also provide explanations for differences in the emergence of drug-resistant mutants and contribute to our understanding of their potential clinical and epidemiological significance.</gtr:abstractText><gtr:technicalSummary>The principal objectives of our current work include: Elucidation of the structure-activity of the ion channels of influenza viruses, the M2 protein of influenza A, the BM2 and NB proteins of influenza B and the CM2 protein of influenza C viruses, in collaboration with Dr. D. Ogden in the Division of Neurophysiology, to define their functional roles in virus infection. A better understanding of resistance to anti-neuramindase drugs in relation to inter-subtype structural differences in the catalytic site, in collaboration with Dr. S. Gamblin, Division of Molecular Structure, and Dr. R. Russell, University of St. Andrews. The ion conductance properties of wt and mutant channels are measured by whole cell patch clamp of mouse erythroleukaemia (MEL) cells stably transformed to express the proteins. Complementary studies of ion transfer and pH modulation by the channels involve the use of fluorescent ion probes and the influenza haemagglutinin as a pH probe to investigate further their roles in virus replication. Mutagenesis studies have identified amino acids which are important for proton selectivity of M2 and its regulation by pH. Two permeabilities, for H+ and for Cl-, are associated with the expression of NB and CM2 channels. Mutagenesis studies, including studies of M2/NB and M2/CM2 chimeras, are aimed at elucidating the inherent conductance properties of the latter two channels.Attempts to understand the significance of the differences in activities of the respective channels in relation to differences in biological characteristics of the 3 types of virus involve reverse genetic studies of recombinant viruses. Studies of channel structure involve both attempts to crystallise the proteins for X-ray analyses and insertion into bilayers for cryo EM analyses. The assays provide a means for more detailed mechanistic studies of the anti M2 drugs, amantadine and rimantadine and related compounds, and the search for other potential specific inhibitors of the NB and CM2 channels. X-ray crystallographic studies identified 2 structurally-distinct phylogenetic groups of neuraminidase subtypes: group 1, including N1, N4, N5 and N8 subtype; group 2, including N2, N3, N6, N7 and N9. An additional cavity adjacent to the catalytic site of group 1 NAs provides the target for development of alternative drugs. Crystallographic studies of mutant proteins will provide a structural explanation for subtype-specific differences in oseltamivir resistance and the molecular bases of various resistance mutations.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1988-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2383073</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Efficacy and immune correlates of H5N1 vaccine</gtr:description><gtr:id>6E10405C-11AF-42FC-933D-31E0E93DF533</gtr:id><gtr:impact>Identification and elucidation of the receptor binding characteristics by D151G mutant NA of recent H3N2 viruses. 
Publications
Multidisciplinary: Immunology, Virology, Biochemistry</gtr:impact><gtr:outcomeId>tFgAWMMCR2s-1</gtr:outcomeId><gtr:partnerContribution>Preparation of human monoclonal antibodies against influenza viruses</gtr:partnerContribution><gtr:piContribution>Development of virus neutralization assay. Characterization of antibodies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting at European Centre for Disease Control</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>E9FB410A-FF74-434C-B3BE-3578F69822F9</gtr:id><gtr:impact>This is part of the EU surveillance system

EU policy is defind at these meetings</gtr:impact><gtr:outcomeId>MZmYRHZtSnY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>163760</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Collaborative Research grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C6D06179-0F71-45AB-9186-5B91CA13D1DC</gtr:id><gtr:outcomeId>oStkQmNBMd90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>204187</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Specific Targeted Project-FP6-2007 (FLUPOL)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>1CF5732C-7EDA-4E71-9D39-D05AFBF82573</gtr:id><gtr:outcomeId>8E8A75A4C570</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>129535</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant 2008</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>63A67D89-708C-4DD4-B289-3D4CEEE0EBEF</gtr:id><gtr:outcomeId>0C3947756E60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Influenza Vaccine Selection</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>AF37702A-E6E1-4E0A-9015-6E602DB4AB15</gtr:id><gtr:impact>This activity meets twice yearly to integrate results of global influenza surveillance to put forward recommendations for the influenza vaccine composition.</gtr:impact><gtr:outcomeId>MXyokwyczdV</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Influenza Virus X31 Variants</gtr:description><gtr:id>3D5759EB-5C80-43B2-B10B-AD6966EF8069</gtr:id><gtr:impact>Transferred to for - profit Institute Feb 2008</gtr:impact><gtr:outcomeId>51E68A27A42</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Influenza Virus X31 Variants</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>S45 Hybridoma</gtr:description><gtr:id>6D1F6064-58DC-4179-85CF-61AD2AAD18C5</gtr:id><gtr:impact>Transferred to company April 2006 for use in their research.</gtr:impact><gtr:outcomeId>C02F25086AF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>S45 HYbridoma</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Ferret antiserum</gtr:description><gtr:id>81C22627-A214-4578-83C0-C27AE106514F</gtr:id><gtr:impact>Transferred to commercial company to aid in vaccine development. July 2008</gtr:impact><gtr:outcomeId>FB592617902</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Ferret antiserum</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C7B1C6A-8EF5-4ECA-B7DE-CEBB16597E1B</gtr:id><gtr:title>A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f94ede5326fdc10a9a00c4996598664e"><gtr:id>f94ede5326fdc10a9a00c4996598664e</gtr:id><gtr:otherNames>Escuret V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5457a242734206.09983825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2BAFB94-2457-44ED-A5D8-928CFD2E0D2A</gtr:id><gtr:title>Evidence that the CM2 protein of influenza C virus can modify the pH of the exocytic pathway of transfected cells.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45c28f64a71415c615e0be7b81ce7ed6"><gtr:id>45c28f64a71415c615e0be7b81ce7ed6</gtr:id><gtr:otherNames>Betakova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>16FB57C24E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>146C044B-98EA-4371-999A-22A813DC063E</gtr:id><gtr:title>High throughput virus plaque quantitation using a flatbed scanner.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5080316229c8050264dc8c1d8bc4c510"><gtr:id>5080316229c8050264dc8c1d8bc4c510</gtr:id><gtr:otherNames>Sullivan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>A2bbKwLrNUT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A674F7E2-8EFA-45E6-921B-3FAE7F759045</gtr:id><gtr:title>Identifying changes in selective constraints: host shifts in influenza.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d820b440caeeb320055d46219d4c55a1"><gtr:id>d820b440caeeb320055d46219d4c55a1</gtr:id><gtr:otherNames>Tamuri AU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>BQggbZe1muW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85A42E5F-4536-4D57-93CE-CDAEAB7FF717</gtr:id><gtr:title>Establishment of mouse erythroleukemia cell lines expressing complete Influenza C virus CM2 protein or chimeric protein consisting of CM2 and Influenza A virus M2.</gtr:title><gtr:parentPublicationTitle>Acta virologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdb36e517d009608075b28200edd333a"><gtr:id>bdb36e517d009608075b28200edd333a</gtr:id><gtr:otherNames>Muraki Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-723X</gtr:issn><gtr:outcomeId>oUBiPaSPmmy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA70A6E9-C72A-4FC4-96E8-CA7616A64988</gtr:id><gtr:title>Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>Bxf6ooeWB8J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9879D3DE-FB2F-4BFB-93DB-118E9310740E</gtr:id><gtr:title>Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80a7be56e1751ece262fecbf341dbc5f"><gtr:id>80a7be56e1751ece262fecbf341dbc5f</gtr:id><gtr:otherNames>Yamada S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>F844831CBED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>717446A7-FA2E-45BE-8081-E46DC13CEB44</gtr:id><gtr:title>[Impact of avian influenza virus H5N1 neuraminidase mutations on the activity of neuraminidase and the sensibility to neuraminidase inhibitors].</gtr:title><gtr:parentPublicationTitle>Zhonghua yi xue za zhi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0376-2491</gtr:issn><gtr:outcomeId>RQmVRmAL7rp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>691F36EB-1301-42B4-BC6C-DC22B6B12D08</gtr:id><gtr:title>Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa1c572e79219fc1ba1b0c9e4c4622c8"><gtr:id>fa1c572e79219fc1ba1b0c9e4c4622c8</gtr:id><gtr:otherNames>Moul?s V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>ZRS3mUPtzVB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6387824F-700B-43B7-A8DA-09FA42347A43</gtr:id><gtr:title>In vitro characterization of naturally occurring influenza H3NA- viruses lacking the NA gene segment: toward a new mechanism of viral resistance?</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697ab0822d009eb1ccd35b41d9f02362"><gtr:id>697ab0822d009eb1ccd35b41d9f02362</gtr:id><gtr:otherNames>Moules V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>sQMMdMTjsS8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A4BD64E-6D05-4731-AD88-AC32D61F54EA</gtr:id><gtr:title>Efficient synthesis of highly active phospha-isosteres of the influenza neuraminidase inhibitor oseltamivir.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8839114230b49985244ce99dba391282"><gtr:id>8839114230b49985244ce99dba391282</gtr:id><gtr:otherNames>Carbain B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>C36854EF7D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5D76892-4373-4BDB-B64E-DCF92838A110</gtr:id><gtr:title>Using non-homogeneous models of nucleotide substitution to identify host shift events: application to the origin of the 1918 'Spanish' influenza pandemic virus.</gtr:title><gtr:parentPublicationTitle>Journal of molecular evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fbe9f7522bdc726f197e55a3d2df077"><gtr:id>1fbe9f7522bdc726f197e55a3d2df077</gtr:id><gtr:otherNames>dos Reis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2844</gtr:issn><gtr:outcomeId>dACgasJqHPQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A076CE5-61F6-4EA7-8986-F3DE59A9D84C</gtr:id><gtr:title>Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5360052184835a92de21a35704db22ac"><gtr:id>5360052184835a92de21a35704db22ac</gtr:id><gtr:otherNames>Lin YP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>HX3eDWmsQJX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5398F2F4-0F17-4A88-9ADB-5131DB9DCDE3</gtr:id><gtr:title>Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00f912b93a39f24dec2b1ab5a406d7c1"><gtr:id>00f912b93a39f24dec2b1ab5a406d7c1</gtr:id><gtr:otherNames>Hurt AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>pm_15873_23_22186145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60FB6390-17FB-4BB2-A708-369D14DF2C95</gtr:id><gtr:title>Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b8420ba7712adbbe774a92ef71e3103"><gtr:id>3b8420ba7712adbbe774a92ef71e3103</gtr:id><gtr:otherNames>Kolocouris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>48B68A24153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39848B9F-9E5F-4FD2-B011-9F062E0C5DBC</gtr:id><gtr:title>Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c2dd76535a6547bb6a7d3a1e3b1f470"><gtr:id>7c2dd76535a6547bb6a7d3a1e3b1f470</gtr:id><gtr:otherNames>Richard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>dFP5ZCoBGHJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>524F76BE-DAF6-498E-BA62-A9BAE40251A4</gtr:id><gtr:title>Influenza H2 haemagglutinin activates B cells via a MyD88-dependent pathway.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87f2a6c5f0b69ccf9816a3400e086dcb"><gtr:id>87f2a6c5f0b69ccf9816a3400e086dcb</gtr:id><gtr:otherNames>Marshall-Clarke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>16BDE117F66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6D983E7-F2A9-4C46-BDA8-38BB49F536AE</gtr:id><gtr:title>Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7af03f6e8d7eff8c4b17531fcf545bc"><gtr:id>b7af03f6e8d7eff8c4b17531fcf545bc</gtr:id><gtr:otherNames>Eleftheratos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>fq5XfsfLPVe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFA3D761-4BD3-4E3F-A7AA-BCDA648D7BD5</gtr:id><gtr:title>Future directions for the European influenza reference laboratory network in influenza surveillance.</gtr:title><gtr:parentPublicationTitle>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec9d165416f02b19c807cd0d04485ee2"><gtr:id>ec9d165416f02b19c807cd0d04485ee2</gtr:id><gtr:otherNames>Goddard N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1025-496X</gtr:issn><gtr:outcomeId>56d97674376992.21610386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAA2F171-08CD-4542-85AF-4DF1C04E875A</gtr:id><gtr:title>Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c2dd76535a6547bb6a7d3a1e3b1f470"><gtr:id>7c2dd76535a6547bb6a7d3a1e3b1f470</gtr:id><gtr:otherNames>Richard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>49B670508A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEE5E748-EC61-4177-943B-826F3F44E0CB</gtr:id><gtr:title>Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f12c9c6b2d626b090cdc2a554ab05584"><gtr:id>f12c9c6b2d626b090cdc2a554ab05584</gtr:id><gtr:otherNames>Childs RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>Jt7vx3Ec6nS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8679EA56-CC52-4EB5-873B-3DCEC698669E</gtr:id><gtr:title>Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ce0be2bd9f59e1bc54c8f3d25891adf"><gtr:id>5ce0be2bd9f59e1bc54c8f3d25891adf</gtr:id><gtr:otherNames>WHO Writing Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn><gtr:outcomeId>d4mSxNGCE73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EA88E2A-4029-4966-98CF-14E89DCBD7B1</gtr:id><gtr:title>The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3429df0f1fb4f1013e2e6f82c8183d45"><gtr:id>3429df0f1fb4f1013e2e6f82c8183d45</gtr:id><gtr:otherNames>Russell RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>95B35F586E5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADA80C74-FB20-478F-8E44-83FABD98DB96</gtr:id><gtr:title>Changing selective pressure during antigenic changes in human influenza H3.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68048b283639eb64eb2988ba7b09df9b"><gtr:id>68048b283639eb64eb2988ba7b09df9b</gtr:id><gtr:otherNames>Blackburne BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>A8360AFAA4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC291869-863A-4354-915C-D9BC7511BD89</gtr:id><gtr:title>Stability and function of the influenza A virus M2 ion channel protein is determined by both extracellular and cytoplasmic domains.</gtr:title><gtr:parentPublicationTitle>Archives of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45c28f64a71415c615e0be7b81ce7ed6"><gtr:id>45c28f64a71415c615e0be7b81ce7ed6</gtr:id><gtr:otherNames>Betakova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-8608</gtr:issn><gtr:outcomeId>bXSagmN1ekz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8E0A6D1-7E10-4823-B785-8CFDE9EEAD61</gtr:id><gtr:title>Structural basis for oseltamivir resistance of influenza viruses.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5326701fa861c5afae566266fd3de076"><gtr:id>5326701fa861c5afae566266fd3de076</gtr:id><gtr:otherNames>Collins PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>eWA8g5toEnA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C248C9CF-F0E4-4BDE-A623-386634688712</gtr:id><gtr:title>Charting the host adaptation of influenza viruses.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fbe9f7522bdc726f197e55a3d2df077"><gtr:id>1fbe9f7522bdc726f197e55a3d2df077</gtr:id><gtr:otherNames>dos Reis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>KJvHXmHE4mZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C28A6F17-11F1-4D37-96BF-7FD54C645768</gtr:id><gtr:title>WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d3ac03788098acd909e11c6f45f15c2"><gtr:id>0d3ac03788098acd909e11c6f45f15c2</gtr:id><gtr:otherNames>Klimov AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15873_23_22917957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>281C8B38-F100-4EDE-8A3E-57664E73F269</gtr:id><gtr:title>Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb25fce01593a2492981eb085594c7d6"><gtr:id>fb25fce01593a2492981eb085594c7d6</gtr:id><gtr:otherNames>Govorkova EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>E2B597896D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B00D3A9-6141-4B1E-A321-4D8FAB27EE12</gtr:id><gtr:title>Comparison of the activities of BM2 protein and its H19 and W23 mutants of influenza B virus with activities of M2 protein and its H37 and W41 mutants of influenza A virus.</gtr:title><gtr:parentPublicationTitle>Archives of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45c28f64a71415c615e0be7b81ce7ed6"><gtr:id>45c28f64a71415c615e0be7b81ce7ed6</gtr:id><gtr:otherNames>Betakova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0304-8608</gtr:issn><gtr:outcomeId>rbfRXFdbnPH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E3D312C-6D6B-4C73-ADD0-70DDDF0FDA7F</gtr:id><gtr:title>Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70398a559be675b0d73f963eef80119d"><gtr:id>70398a559be675b0d73f963eef80119d</gtr:id><gtr:otherNames>Ilyushina NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>270E5DCD8F8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E57E372-DAA4-4F91-A5F4-22D237A4E69E</gtr:id><gtr:title>Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59833a17d6c99359fae1ad80f7124606"><gtr:id>59833a17d6c99359fae1ad80f7124606</gtr:id><gtr:otherNames>Leneva IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>ESAQbFTrkrq</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117512708</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>